Exercise, Hypertension, and Gut Dysbiosis in African Americans
Effects of Exercise on Hypertension and Gut Dysbiosis in African Americans
1 other identifier
interventional
36
1 country
1
Brief Summary
African Americans have the greatest burden of endothelial dysfunction and hypertension. Recently, gut microbial dysbiosis (a term that describes a poorly diverse gut microbial profile and lower short-chain fatty acid (SCFA) production) has been linked to hypertension and may be involved in the pathogenesis of hypertension in African Americans. African Americans have been reported to have lower gut SCFA and SCFA can reduce blood pressure. Exercise reduces blood pressure and improves gut dysbiosis (increases SCFA) and likely couples' improvements in gut microbial health and vascular function to reduce blood pressure. Thus, the goals of this research are to fill a critical void concerning the interaction of gut dysbiosis, hypertension, and utilizing exercise to identify gut microbial adaptations that accompany a reduction in blood pressure. The short-term implications of this work will advance the clinical communities understanding of the relationship between dysbiosis and the pathogenesis of hypertension in African Americans, while long term implications will promote identifying adaptable gut microbes associated with vascular health to aid in amending treatment strategies for hypertension.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable hypertension
Started Jun 2019
Longer than P75 for not_applicable hypertension
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 26, 2019
CompletedFirst Posted
Study publicly available on registry
April 1, 2019
CompletedStudy Start
First participant enrolled
June 1, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2030
ExpectedStudy Completion
Last participant's last visit for all outcomes
June 1, 2030
April 13, 2026
April 1, 2026
11 years
January 26, 2019
April 8, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Blood Pressure
Expect a change in systolic and diastolic BP
3 months
Gut Dysbiosis
Expect an change in microbial diversity and SCFA producing microbes
3 months
Study Arms (1)
Hypertension (Exercise Intervention)
EXPERIMENTALParticipants with hypertension will submit blood and fecal samples for comparison to control participants with normal blood pressure. Control group will only donate fecal and blood samples and will not participate in the exercise intervention. Participants with hypertension will also perform 3 months of supervised aerobic exercise (5 days/week) and submit blood and fecal samples every 4 weeks until the completion of the study.
Interventions
the proposed research will: 1) Characterize gut microbial community structure in AA with hypertension in two important compartments that make up the overall gut bacteria in the colon (fecal and colon mucosa); 2) Quantify the relationship between aerobic exercise training and gut bacteria to identify SCFA microbes that adapt to exercise and benefit BP.
Eligibility Criteria
You may qualify if:
- Sedentary (regular aerobic exercise frequency ≤2 times per week and duration ≤20 minutes per session; sedentary profession);
- years of age;
- Control normotensive (systolic BP: 90-120 mmHg/diastolic BP: 60-80 mmHg)
- Elevated to Stage 1 Hypertension (systolic BP: 120-129 mmHg/diastolic BP: 80-89 mmHg) and/or stage 1 hypertension (systolic BP: 130-159 mmHg/diastolic BP: 90-99 mmHg).
You may not qualify if:
- Diagnosed with any of the following:
- Uncontrolled hypertension, stroke, history of heart attack, heart disease;
- Metabolic disease (diabetes mellitus);
- Inflammatory diseases (inflammatory bowel disease(s), rheumatoid arthritis, and systemic lupus erythematosus);
- Kidney stones or gallbladder problems;
- Kidney disease;
- Liver disease;
- Lung disease;
- Cancer within the previous 6 months; (11) pregnant females;
- Peripheral vascular disease;
- Taking hypertension medications or those known to affect inflammation or metabolic function (anti-inflammatories, statins, thyroid medication) in the past 1 month;
- Currently smoking;
- Other conditions that would exclude vigorous exercise (\>2mV ST-segment depression or CVD signs and symptoms during the screening graded exercise test).
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
North Carolina A&T State University
Greensboro, North Carolina, 27411, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Marc Cook, PhD
North Carolina Agriculture & Technical State University
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- BASIC SCIENCE
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant Professor of Exercise Immunology
Study Record Dates
First Submitted
January 26, 2019
First Posted
April 1, 2019
Study Start
June 1, 2019
Primary Completion (Estimated)
June 1, 2030
Study Completion (Estimated)
June 1, 2030
Last Updated
April 13, 2026
Record last verified: 2026-04
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, CSR
- Time Frame
- Data will be available within 6 months of the end of the study
De-identifiable IPD will be made available for all primary and secondary data measures.